Acadia Pharmaceuticals Inc. saw its market cap double Monday following positive Phase IIb findings showing that its investigational compound ACP-103 improved the efficacy of a widely prescribed schizophrenia drug and also minimized its side effects. (BioWorld Today) Read More
